Annexon, Inc. (ANNX) stock
ANNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.92−0.05 (-1.26%)
Close on Nov 13, 2026Market cap $801.42MP/E –Yield 0.00%
Annexon r&d expenses
Research and development expenses are spending on new products and technology.
Annexon's R&D Expenses for the twelve months ending Sep 30, 2026 was $166.40M, down 10.2% year over year. For fiscal 2025 it was $184.70M, up 54.6% from the year before. The highest annual figure on record is $184.70M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $184.70M | +54.6% |
| FY2024 | Dec 31, 2024 | $119.45M | +5.0% |
| FY2023 | Dec 31, 2023 | $113.76M | +1.1% |
| FY2022 | Dec 31, 2022 | $112.50M | +12.4% |
| FY2021 | Dec 31, 2021 | $100.07M | +103.1% |
| FY2020 | Dec 31, 2020 | $49.27M | +100.9% |
| FY2019 | Dec 31, 2019 | $24.52M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $41.37M | -16.8% |
| Q2 FY2026 | Jun 30, 2026 | $46.59M | +5.5% |
| Q1 FY2026 | Mar 31, 2026 | $35.79M | -25.7% |
| Q4 FY2025 | Dec 31, 2025 | $42.66M | -1.6% |
| Q3 FY2025 | Sep 30, 2025 | $49.70M | +65.1% |
| Q2 FY2025 | Jun 30, 2025 | $44.16M | +76.5% |
| Q1 FY2025 | Mar 31, 2025 | $48.18M | +129.8% |
| Q4 FY2024 | Dec 31, 2024 | $43.35M | +86.3% |
| Q3 FY2024 | Sep 30, 2024 | $30.11M | +7.9% |
| Q2 FY2024 | Jun 30, 2024 | $25.03M | -17.3% |
| Q1 FY2024 | Mar 31, 2024 | $20.96M | -35.2% |
| Q4 FY2023 | Dec 31, 2023 | $23.27M | -18.5% |
| Q3 FY2023 | Sep 30, 2023 | $27.89M | +0.1% |
| Q2 FY2023 | Jun 30, 2023 | $30.25M | +3.9% |
| Q1 FY2023 | Mar 31, 2023 | $32.35M | +19.8% |
| Q4 FY2022 | Dec 31, 2022 | $28.54M | +4.8% |
| Q3 FY2022 | Sep 30, 2022 | $27.86M | +1.0% |
| Q2 FY2022 | Jun 30, 2022 | $29.11M | +18.5% |
| Q1 FY2022 | Mar 31, 2022 | $27.00M | +30.5% |
| Q4 FY2021 | Dec 31, 2021 | $27.22M | +51.3% |
| Q3 FY2021 | Sep 30, 2021 | $27.58M | +134.2% |
| Q2 FY2021 | Jun 30, 2021 | $24.57M | +164.6% |
| Q1 FY2021 | Mar 31, 2021 | $20.70M | +102.6% |
| Q4 FY2020 | Dec 31, 2020 | $17.99M | +164.8% |
| Q3 FY2020 | Sep 30, 2020 | $11.78M | +66.1% |
| Q2 FY2020 | Jun 30, 2020 | $9.29M | +55.1% |
| Q1 FY2020 | Mar 31, 2020 | $10.22M | – |
| Q4 FY2019 | Dec 31, 2019 | $6.80M | – |
| Q3 FY2019 | Sep 30, 2019 | $7.09M | – |
| Q2 FY2019 | Jun 30, 2019 | $5.99M | – |
See a number that looks wrong?